-
1
-
-
84896721523
-
Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care
-
Kelly RJ, Smith TJ. Delivering maximum clinical benefit at an affordable price: engaging stakeholders in cancer care. Lancet Oncol. 2014;15(3):e112–8
-
(2014)
Lancet Oncol.
, vol.15
, Issue.3
, pp. e112-e118
-
-
Kelly, R.J.1
Smith, T.J.2
-
2
-
-
84922419758
-
Pricing in the market for anticancer drugs
-
Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. J Econ Perspect. 2015;29(1):139–62
-
(2015)
J Econ Perspect.
, vol.29
, Issue.1
, pp. 139-162
-
-
Howard, D.H.1
Bach, P.B.2
Berndt, E.R.3
Conti, R.M.4
-
3
-
-
84975261142
-
Value: the next frontier in cancer care
-
Goulart BH. Value: the next frontier in cancer care. Oncologist. 2016;21(6):651–3
-
(2016)
Oncologist.
, vol.21
, Issue.6
, pp. 651-653
-
-
Goulart, B.H.1
-
4
-
-
84971623153
-
Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis
-
Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032
-
(2016)
PLoS Med.
, vol.13
, Issue.5
-
-
Iyengar, S.1
Tay-Teo, K.2
Vogler, S.3
Beyer, P.4
Wiktor, S.5
de Joncheere, K.6
-
5
-
-
84890841035
-
Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries
-
Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries. Orphanet J Rare Dis. 2013;8:198
-
(2013)
Orphanet J Rare Dis.
, vol.8
, pp. 198
-
-
Morel, T.1
Arickx, F.2
Befrits, G.3
Siviero, P.4
van der Meijden, C.5
Xoxi, E.6
-
6
-
-
84910654404
-
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
-
Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124:39–47
-
(2015)
Soc Sci Med.
, vol.124
, pp. 39-47
-
-
Ferrario, A.1
Kanavos, P.2
-
7
-
-
84916931880
-
Are new models needed to optimize the utilization of new medicines to sustain healthcare systems?
-
Godman B, Malmstrom RE, Diogene E, Gray A, Jayathissa S, Timoney A, et al. Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? Expert Rev Clin Pharmacol. 2015;8(1):77–94
-
(2015)
Expert Rev Clin Pharmacol.
, vol.8
, Issue.1
, pp. 77-94
-
-
Godman, B.1
Malmstrom, R.E.2
Diogene, E.3
Gray, A.4
Jayathissa, S.5
Timoney, A.6
-
8
-
-
84949430283
-
Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability
-
Montilla S, Xoxi E, Russo P, Cicchetti A, Pani L. Monitoring registries at Italian Medicines Agency: fostering access, guaranteeing sustainability. Int J Technol Assess Health Care. 2015;31(4):210–3
-
(2015)
Int J Technol Assess Health Care.
, vol.31
, Issue.4
, pp. 210-213
-
-
Montilla, S.1
Xoxi, E.2
Russo, P.3
Cicchetti, A.4
Pani, L.5
-
9
-
-
85008481918
-
How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries
-
Vogler S, Paris V, Ferrario A, Wirtz VJ, de Joncheere K, Schneider P, et al. How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries. Appl Health Econ Health Policy. 2017;15(3):307–21
-
(2017)
Appl Health Econ Health Policy.
, vol.15
, Issue.3
, pp. 307-321
-
-
Vogler, S.1
Paris, V.2
Ferrario, A.3
Wirtz, V.J.4
de Joncheere, K.5
Schneider, P.6
-
10
-
-
85018384674
-
Managed entry agreements for oncology drugs: lessons from the European experience to inform the future
-
Pauwels K, Huys I, Vogler S, Casteels M, Simoens S. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;8:171
-
(2017)
Front Pharmacol.
, vol.8
, pp. 171
-
-
Pauwels, K.1
Huys, I.2
Vogler, S.3
Casteels, M.4
Simoens, S.5
-
11
-
-
84908203910
-
Accelerated access to innovative medicines for patients in need
-
Baird LG, Banken R, Eichler HG, Kristensen FB, Lee DK, Lim JC, et al. Accelerated access to innovative medicines for patients in need. Clin Pharmacol Ther. 2014;96(5):559–71
-
(2014)
Clin Pharmacol Ther.
, vol.96
, Issue.5
, pp. 559-571
-
-
Baird, L.G.1
Banken, R.2
Eichler, H.G.3
Kristensen, F.B.4
Lee, D.K.5
Lim, J.C.6
-
12
-
-
85060898931
-
-
Accessed 24 Sep 2018
-
HTA. Glossary 2018. www.htaglossary.net. Accessed 24 Sep 2018
-
Glossary 2018
-
-
-
15
-
-
85062480015
-
-
KCE Reports 283. D/2017/10.273/15
-
Lepage-Nefkens I, Douw K, Mantjes G, de Graaf G, Leroy R, Cleemput I. Horizon scanning for pharmaceuticals: proposal for the BeNeLuxA collaboration. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE). 2017. KCE Reports 283. D/2017/10.273/15. https://kce.fgov.be/en/horizon-scanning-for-pharmaceuticals-proposal-for-the-beneluxa-collaboration
-
(2017)
Horizon scanning for pharmaceuticals: Proposal for the BeNeLuxA collaboration. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE)
-
-
Lepage-Nefkens, I.1
Douw, K.2
Mantjes, G.3
de Graaf, G.4
Leroy, R.5
Cleemput, I.6
-
16
-
-
85060900421
-
-
Personal communication. 5 Apr
-
Christensen AB. Personal communication. 5 Apr 2018
-
(2018)
-
-
Christensen, A.B.1
-
17
-
-
4043168324
-
Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system
-
Simpson S, Hyde C, Cook A, Packer C, Stevens A. Assessing the accuracy of forecasting: applying standard diagnostic assessment tools to a health technology early warning system. Int J Technol Assess Health Care. 2004;20(3):381–4
-
(2004)
Int J Technol Assess Health Care.
, vol.20
, Issue.3
, pp. 381-384
-
-
Simpson, S.1
Hyde, C.2
Cook, A.3
Packer, C.4
Stevens, A.5
-
18
-
-
34250710525
-
Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems
-
Murphy K, Packer C, Stevens A, Simpson S. Effective early warning systems for new and emerging health technologies: developing an evaluation framework and an assessment of current systems. Int J Technol Assess Health Care. 2007;23(3):324–30
-
(2007)
Int J Technol Assess Health Care.
, vol.23
, Issue.3
, pp. 324-330
-
-
Murphy, K.1
Packer, C.2
Stevens, A.3
Simpson, S.4
-
19
-
-
84866383656
-
Analyzing 10 years of early awareness and alert activity in the United Kingdom
-
Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United Kingdom. Int J Technol Assess Health Care. 2012;28(3):308–14
-
(2012)
Int J Technol Assess Health Care.
, vol.28
, Issue.3
, pp. 308-314
-
-
Packer, C.1
Fung, M.2
Stevens, A.3
-
20
-
-
84960089335
-
Looking back on 5 years of horizon scanning in oncology
-
Nachtnebel A, Breuer J, Willenbacher W, Bucsics A, Krippl P, Wild C. Looking back on 5 years of horizon scanning in oncology. Int J Technol Assess Health Care. 2016;32(1–2):54–60
-
(2016)
Int J Technol Assess Health Care.
, vol.32
, Issue.1-2
, pp. 54-60
-
-
Nachtnebel, A.1
Breuer, J.2
Willenbacher, W.3
Bucsics, A.4
Krippl, P.5
Wild, C.6
-
21
-
-
85060901128
-
-
(Prepared by the Mathematica Policy Research for ECRI Institute under Contract No. 290-2010-00006-C.) AHRQ Publication No. 16-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; May
-
Duda N, Fleming C, Kirwan B, Roff B, Rich E. Evaluation of the AHRQ Healthcare Horizon Scanning System. (Prepared by the Mathematica Policy Research for ECRI Institute under Contract No. 290-2010-00006-C.) AHRQ Publication No. 16-EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality; May 2016. https://www.effectivehealthcare.ahrq.gov/reports/final.cfm
-
(2016)
Evaluation of the AHRQ Healthcare Horizon Scanning System
-
-
Duda, N.1
Fleming, C.2
Kirwan, B.3
Roff, B.4
Rich, E.5
-
22
-
-
85030626951
-
The early awareness and alert system in Sweden: history and current status
-
Eriksson I, Wettermark B, Persson M, Edstrom M, Godman B, Lindhe A, et al. The early awareness and alert system in Sweden: history and current status. Front Pharmacol. 2017;8:674
-
(2017)
Front Pharmacol.
, vol.8
, pp. 674
-
-
Eriksson, I.1
Wettermark, B.2
Persson, M.3
Edstrom, M.4
Godman, B.5
Lindhe, A.6
-
23
-
-
85060903690
-
-
Accessed 24 Sep 2018
-
EMA. EMA 2018. www.ema.europa.eu. Accessed 24 Sep 2018
-
(2018)
-
-
-
24
-
-
85054562186
-
-
Accessed 24 Sep 2018
-
Swedish eHealth Agency. 2018. https://www.ehalsomyndigheten.se/other-languages/english/. Accessed 24 Sep 2018
-
(2018)
-
-
-
25
-
-
85041918897
-
The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations
-
Eriksson I, Komen J, Piehl F, Malmström RE, Wettermark B, von Euler M. The changing multiple sclerosis treatment landscape: impact of new drugs and treatment recommendations. Eur J Clin Pharmacol. 2018;74(5):663–70
-
(2018)
Eur J Clin Pharmacol.
, vol.74
, Issue.5
, pp. 663-670
-
-
Eriksson, I.1
Komen, J.2
Piehl, F.3
Malmström, R.E.4
Wettermark, B.5
von Euler, M.6
-
26
-
-
85033471480
-
Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
-
Eriksson I, Cars T, Piehl F, Malmström RE, Wettermark B, von Euler M. Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study. Eur J Clin Pharmacol. 2018;74(2):219–26
-
(2018)
Eur J Clin Pharmacol.
, vol.74
, Issue.2
, pp. 219-226
-
-
Eriksson, I.1
Cars, T.2
Piehl, F.3
Malmström, R.E.4
Wettermark, B.5
von Euler, M.6
-
27
-
-
85045086003
-
Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden
-
Frisk P, Aggefors K, Cars T, Feltelius N, Loov SA, Wettermark B, et al. Introduction of the second-generation direct-acting antivirals (DAAs) in chronic hepatitis C: a register-based study in Sweden. Eur J Clin Pharmacol. 2018;74(7):971–8
-
(2018)
Eur J Clin Pharmacol.
, vol.74
, Issue.7
, pp. 971-978
-
-
Frisk, P.1
Aggefors, K.2
Cars, T.3
Feltelius, N.4
Loov, S.A.5
Wettermark, B.6
-
28
-
-
33845386511
-
Selecting new health technologies for evaluation: can clinical experts predict which new anticancer drugs will impact Danish health care?
-
Douw K, Vondeling H. Selecting new health technologies for evaluation: can clinical experts predict which new anticancer drugs will impact Danish health care? Soc Sci Med. 2007;64(2):283–6
-
(2007)
Soc Sci Med.
, vol.64
, Issue.2
, pp. 283-286
-
-
Douw, K.1
Vondeling, H.2
-
29
-
-
85054572596
-
-
Accessed 24 Sep 2018
-
The Swedish Early Awareness and Alert System. Shingrix early assessment report 2017. http://www.janusinfo.se/Documents/Nationellt_inforande_av_nya_lakemedel/Shingrix-tidig-bedomningsrapport170519.pdf. Accessed 24 Sep 2018
-
(2017)
Shingrix Early Assessment Report
-
-
-
30
-
-
85044634269
-
mRNA vaccines: a new era in vaccinology
-
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines: a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–79
-
(2018)
Nat Rev Drug Discov.
, vol.17
, Issue.4
, pp. 261-279
-
-
Pardi, N.1
Hogan, M.J.2
Porter, F.W.3
Weissman, D.4
|